Company Profile

Top Page > Company Profile > Our Business > Life Science Translational Research (LSTR) Business

Life Science Translational Research (LSTR) Business

Research Reagents Directed toward the Development and Commercialization of Clinical Diagnostics

Immuno-Oncology and MHC Tetramer business

MBL is globally supporting cancer immunotherapy development with MHC tetramers.

Conventionally, cancers have been treated by surgical interventions, radiation therapies and chemotherapies; however, in recent years, more attentions have been devoted to cancer immunotherapies.
Cancer immunotherapy is a type of therapy used to fight cancers by utilizing human body’s natural immune system. Immunotherapeutic agents have attracted particularly strong interest since the U.S. FDA approval of the first immune checkpoint inhibitors, and the development of drugs in this class is now accelerating throughout the world.
One example of new cancer immunotherapy is CAR T-cell therapy, which uses the patient’s own immune cells, genetically modified to contain genes of antibodies capable of recognizing marker molecules of cancer cells, enabling them to target and kill cancer cells specifically. CAR T-cell therapy has gained approval from the U.S. FDA for some types of leukemia, and clinical trials have been started in Japan.
Another example of cancer immunotherapy is neo-antigen therapy, which is designed to comprehensively analyze tumor-specific gene mutations using next-generation sequencers and to enhance immune response to the mutated proteins using peptide vaccines. Clinical trials of this therapy are currently on-going, targeting several cancers, in the U.S.

MHC tetramer reagents that MBL has developed and is marketing are reagents indicated for the detection of immune cells specifically responsive to marker molecules that individual cancer cells contain. The use of MHC tetramer reagents can determine how many immune cells specifically responsive to certain cancer cells have increased in various types of cancer immunotherapies and thereby enable evaluation of the ecacy of cancer therapies.
MBL has supported research and development activities for new cancer immunotherapies by providing MHC tetramer reagents in basic research area throughout the world for more than 10 years. MBL aims to be a leading global manufacturer of reagents in this area and, at the same time, strive for the development of new products to support cancer immunotherapies, such as immune monitoring reagents and companion diagnostics, to contribute to the further advancement in personalized medicine and precision medicine.


MBL is researching and developing antibodies and assay kits by utilizing its core technologies of antibody production and supporting the academia and pharmaceutical industry in their research activities. Our company’s high-quality antibody and kit products have long been highly esteemed among researchers in molecular (cellular) biology and are broadly supporting their basic laboratory to clinical research activities.

MBL supports the academia and industry with various technologies and know-how on antibody production, modification, and labeling.

Fluorescent Proteins

MBL has extensive lineups of products and technologies using unique fluorescent proteins. These are essential technologies and tools for the discovery of molecular target drugs at an early phase of new drug discovery and hence are widely used in research and development by pharmaceutical companies and research institutes worldwide.

Full Site